BioArctic and Eisai Ink research agreement on AD BAN2802


BioArctic AB and Eisai Co., Ltd. have entered into a research evaluation agreement for BAN2802, a potential new therapy that combines BioArctic’s BrainTransporter technology with an undisclosed Alzheimer’s disease drug candidate. At the conclusion of the collaboration, Eisai will evaluate the data generated and decide whether to exercise its option to license BAN2802 for the treatment of Alzheimer’s disease.

BioArctic and Eisai have a long-standing collaboration dating back to 2005 to develop and commercialize drugs to treat Alzheimer’s disease. The collaboration resulted in Leqembi (lecanemab), the first approved drug that has been shown to slow the progression of early-stage Alzheimer’s disease. The new collaboration will build on the two companies’ shared knowledge in the field of Alzheimer’s disease. Costs will be shared for the Research Evaluation Program, which will evaluate the next generation of disease-modifying therapies for Alzheimer’s disease.

“I’m delighted that our Brain Transporter technology continues to make such good progress and that we have now signed our first agreement utilizing the platform. I believe this technology has huge potential to improve many different projects and support companies in their pursuit of Gunilla Osswald, CEO of BioArctic, said: “Eisai has been a valued partner of BioArctic for the past two decades, and we are very pleased to expand and deepen our relationship through this new research evaluation agreement on BAN2802. ”

BioArctic’s BrainTransporter is a technology that actively transports biologics across the blood-brain barrier and into the brain. The technology has the potential to create faster, stronger treatments that target the brain.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top